Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 562

1.

Symptomatology and neuropsychological functioning in cannabis using subjects at ultra-high risk for developing psychosis and healthy controls.

Korver N, Nieman DH, Becker HE, van de Fliert JR, Dingemans PH, de Haan L, Spiering M, Schmitz N, Linszen DH.

Aust N Z J Psychiatry. 2010 Mar;44(3):230-6. doi: 10.3109/00048670903487118.

PMID:
20180725
[PubMed - indexed for MEDLINE]
2.

Baseline differences in clinical symptomatology between ultra high risk subjects with and without a transition to psychosis.

Velthorst E, Nieman DH, Becker HE, van de Fliert R, Dingemans PM, Klaassen R, de Haan L, van Amelsvoort T, Linszen DH.

Schizophr Res. 2009 Apr;109(1-3):60-5. doi: 10.1016/j.schres.2009.02.002. Epub 2009 Mar 9.

PMID:
19272756
[PubMed - indexed for MEDLINE]
3.

Antisaccade task performance in patients at ultra high risk for developing psychosis.

Nieman D, Becker H, van de Fliert R, Plat N, Bour L, Koelman H, Klaassen M, Dingemans P, Niessen M, Linszen D.

Schizophr Res. 2007 Sep;95(1-3):54-60. Epub 2007 Jul 26.

PMID:
17656071
[PubMed - indexed for MEDLINE]
4.

Cannabis use in patients with a first psychotic episode and subjects at ultra high risk of psychosis: impact on psychotic- and pre-psychotic symptoms.

Machielsen M, van der Sluis S, de Haan L.

Aust N Z J Psychiatry. 2010 Aug;44(8):721-8. doi: 10.3109/00048671003689710.

PMID:
20636193
[PubMed - indexed for MEDLINE]
5.

Subjective effects of cannabis before the first psychotic episode.

Peters BD, de Koning P, Dingemans P, Becker H, Linszen DH, de Haan L.

Aust N Z J Psychiatry. 2009 Dec;43(12):1155-62. doi: 10.3109/00048670903179095.

PMID:
20001415
[PubMed - indexed for MEDLINE]
6.

Verbal fluency as a possible predictor for psychosis.

Becker HE, Nieman DH, Dingemans PM, van de Fliert JR, De Haan L, Linszen DH.

Eur Psychiatry. 2010 Mar;25(2):105-10. doi: 10.1016/j.eurpsy.2009.08.003. Epub 2009 Dec 14.

PMID:
20005685
[PubMed - indexed for MEDLINE]
7.

High remission rates from an initial ultra-high risk state for psychosis.

Simon AE, Umbricht D.

Schizophr Res. 2010 Feb;116(2-3):168-72. doi: 10.1016/j.schres.2009.10.001. Epub 2009 Oct 24.

PMID:
19854621
[PubMed - indexed for MEDLINE]
8.

Effects of cannabis use on event related potentials in subjects at ultra high risk for psychosis and healthy controls.

van Tricht MJ, Harmsen EC, Koelman JH, Bour LJ, van Amelsvoort TA, Linszen DH, de Haan L, Nieman DH.

Int J Psychophysiol. 2013 May;88(2):149-56. doi: 10.1016/j.ijpsycho.2013.03.012. Epub 2013 Mar 27.

PMID:
23541998
[PubMed - indexed for MEDLINE]
9.

[Effect of comorbid substance use on neuropsychological performance in subjects with psychotic or mood disorders].

Liraud F, Verdoux H.

Encephale. 2002 Mar-Apr;28(2):160-8. French.

PMID:
11972143
[PubMed - indexed for MEDLINE]
10.

Cognitive functioning in children and adolescents in their first episode of psychosis: differences between previous cannabis users and nonusers.

de la Serna E, Mayoral M, Baeza I, Arango C, Andrés P, Bombin I, González C, Rapado M, Robles O, Rodríguez-Sánchez JM, Zabala A, Castro-Fornieles J.

J Nerv Ment Dis. 2010 Feb;198(2):159-62. doi: 10.1097/NMD.0b013e3181cc0d41.

PMID:
20145493
[PubMed - indexed for MEDLINE]
11.

Cannabis and cognitive performance in psychosis: a cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings.

Meijer JH, Dekker N, Koeter MW, Quee PJ, van Beveren NJ, Meijer CJ; Genetic Risk and Outcome of Psychosis (GROUP) Investigators.

Psychol Med. 2012 Apr;42(4):705-16. doi: 10.1017/S0033291711001656. Epub 2011 Sep 7.

PMID:
21899795
[PubMed - indexed for MEDLINE]
12.

Different psychological effects of cannabis use in adolescents at genetic high risk for schizophrenia and with attention deficit/hyperactivity disorder (ADHD).

Hollis C, Groom MJ, Das D, Calton T, Bates AT, Andrews HK, Jackson GM, Liddle PF.

Schizophr Res. 2008 Oct;105(1-3):216-23. doi: 10.1016/j.schres.2008.07.010. Epub 2008 Sep 2.

PMID:
18768298
[PubMed - indexed for MEDLINE]
13.

Clinical and neurocognitive profiles of subjects at high risk for psychosis with and without obsessive-compulsive symptoms.

Hur JW, Shin NY, Jang JH, Shim G, Park HY, Hwang JY, Kim SN, Yoo JH, Hong KS, Kwon JS.

Aust N Z J Psychiatry. 2012 Feb;46(2):161-9. doi: 10.1177/0004867411432851.

PMID:
22311532
[PubMed - indexed for MEDLINE]
14.

Memory impairments identified in people at ultra-high risk for psychosis who later develop first-episode psychosis.

Brewer WJ, Francey SM, Wood SJ, Jackson HJ, Pantelis C, Phillips LJ, Yung AR, Anderson VA, McGorry PD.

Am J Psychiatry. 2005 Jan;162(1):71-8.

PMID:
15625204
[PubMed - indexed for MEDLINE]
15.

Caudate nucleus volume in individuals at ultra-high risk of psychosis: a cross-sectional magnetic resonance imaging study.

Hannan KL, Wood SJ, Yung AR, Velakoulis D, Phillips LJ, Soulsby B, Berger G, McGorry PD, Pantelis C.

Psychiatry Res. 2010 Jun 30;182(3):223-30. doi: 10.1016/j.pscychresns.2010.02.006. Epub 2010 May 20.

PMID:
20488675
[PubMed - indexed for MEDLINE]
16.

[Cannabis and schizophrenia: demographic and clinical correlates].

Dervaux A, Laqueille X, Bourdel MC, Leborgne MH, Olié JP, Lôo H, Krebs MO.

Encephale. 2003 Jan-Feb;29(1):11-7. French.

PMID:
12640322
[PubMed - indexed for MEDLINE]
17.

Insular cortex gray matter changes in individuals at ultra-high-risk of developing psychosis.

Takahashi T, Wood SJ, Yung AR, Phillips LJ, Soulsby B, McGorry PD, Tanino R, Zhou SY, Suzuki M, Velakoulis D, Pantelis C.

Schizophr Res. 2009 Jun;111(1-3):94-102. doi: 10.1016/j.schres.2009.03.024. Epub 2009 Apr 5.

PMID:
19349150
[PubMed - indexed for MEDLINE]
18.

Fewer neurological soft signs among first episode psychosis patients with heavy cannabis use.

Ruiz-Veguilla M, Gurpegui M, Barrigón ML, Ferrín M, Marín E, Rubio JL, Gutiérrez B, Pintor A, Cervilla J.

Schizophr Res. 2009 Feb;107(2-3):158-64. doi: 10.1016/j.schres.2008.08.001. Epub 2008 Sep 21.

PMID:
18805673
[PubMed - indexed for MEDLINE]
19.

[Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].

Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B.

Encephale. 2008 Dec;34(6):557-62. doi: 10.1016/j.encep.2007.12.005. Epub 2008 Jul 9. French.

PMID:
19081451
[PubMed - indexed for MEDLINE]
20.

The course of neurocognition and social functioning in individuals at ultra high risk for psychosis.

Niendam TA, Bearden CE, Zinberg J, Johnson JK, O'Brien M, Cannon TD.

Schizophr Bull. 2007 May;33(3):772-81. Epub 2007 Apr 9.

PMID:
17420177
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk